Maximilian Gebhart, Mostafa Alilou, Ronald Gust, Stefan Salcher
{"title":"Circumventing Imatinib resistance in CML: Novel Telmisartan-based cell death modulators with improved activity and stability","authors":"Maximilian Gebhart, Mostafa Alilou, Ronald Gust, Stefan Salcher","doi":"10.1016/j.ejmech.2024.117106","DOIUrl":null,"url":null,"abstract":"Drug resistance presents a significant challenge in cancer therapy, which has led to intensive research in resistance mechanisms and new therapeutic strategies. In chronic myeloid leukemia (CML), the introduction of Imatinib, the first tyrosine kinase inhibitor (TKI), drastically changed the outcome for patients. However, complete remission still cannot be achieved in a large number of patients in the long term. Therefore, there is a great interest in the design of new drugs to target TKI-resistant cancer cells. A promising approach to enhance the efficacy of Imatinib is the simultaneous application of cell death modulators derived from the Angiotensin II type 1 receptor blocker Telmisartan. The methyl ester (<strong>3a</strong>) of 4‘-((2-propyl-1<em>H</em>-benzo[<em>d</em>]imidazol-1-yl)methyl)-[1,1’-biphenyl]-2-carboxylic acid (LEAD-acid (<strong>4</strong>)), which is the structural core of Telmisartan, has already been shown to abolish the resistance of Imatinib in TKI-insensitive CML cells at a concentration of 5 μM. As the ester was expected to be unstable in a biological environment, this study attempted to increase the stability through structural modifications. The methyl group was exchanged for longer (<strong>3b</strong> (ethyl), <strong>3c</strong> (propyl), <strong>3d</strong> (butyl) and branched (<strong>3e</strong> (isopropyl), <strong>3f</strong> (<em>tert</em>-butyl)) alkyl chains as well as a phenyl (<strong>3g</strong>) and 4-phenoxyphenyl (<strong>3h</strong>) group. Furthermore, the esters were bioisosterically replaced with a respective substituted carboxamide (<strong>5a-h</strong>). The LEAD-amides (<strong>5a-h</strong>) showed high stability against esterases, while amidases cleaved only the carboxamides with short alkyl chains to a small extent. Esterases hydrolyzed the LEAD-alkylesters (<strong>3a-d</strong>) dependent on the chain length with τ<sub>½</sub> = 55-82 min. Esters with branched alkyl chains were stable and introduction of aromatic rings increased the half-life to τ<sub>½</sub> = 280 min and 360 min. In cell culture medium, only <strong>3a-d</strong> degraded to 67-78 % after 72 h. However, the uptake studies showed that approximatly 80 % of the esters were accumulated in the cell within the first 1-3 h of incubation. Therefore, it can be concluded that the intact LEAD-esters and LEAD-amides caused the biological effects. The compounds were non-cytotoxic and efficiently sensitized KD225 (K562-resistant) CML cells to Imatinib at a half-maximal sensitizing concentration (SC<sub>50</sub>) of 1.5-2.9 μM (ester derivatives) and 1.3-11.2 μM (amide derivatives).","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"62 1","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ejmech.2024.117106","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Drug resistance presents a significant challenge in cancer therapy, which has led to intensive research in resistance mechanisms and new therapeutic strategies. In chronic myeloid leukemia (CML), the introduction of Imatinib, the first tyrosine kinase inhibitor (TKI), drastically changed the outcome for patients. However, complete remission still cannot be achieved in a large number of patients in the long term. Therefore, there is a great interest in the design of new drugs to target TKI-resistant cancer cells. A promising approach to enhance the efficacy of Imatinib is the simultaneous application of cell death modulators derived from the Angiotensin II type 1 receptor blocker Telmisartan. The methyl ester (3a) of 4‘-((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1’-biphenyl]-2-carboxylic acid (LEAD-acid (4)), which is the structural core of Telmisartan, has already been shown to abolish the resistance of Imatinib in TKI-insensitive CML cells at a concentration of 5 μM. As the ester was expected to be unstable in a biological environment, this study attempted to increase the stability through structural modifications. The methyl group was exchanged for longer (3b (ethyl), 3c (propyl), 3d (butyl) and branched (3e (isopropyl), 3f (tert-butyl)) alkyl chains as well as a phenyl (3g) and 4-phenoxyphenyl (3h) group. Furthermore, the esters were bioisosterically replaced with a respective substituted carboxamide (5a-h). The LEAD-amides (5a-h) showed high stability against esterases, while amidases cleaved only the carboxamides with short alkyl chains to a small extent. Esterases hydrolyzed the LEAD-alkylesters (3a-d) dependent on the chain length with τ½ = 55-82 min. Esters with branched alkyl chains were stable and introduction of aromatic rings increased the half-life to τ½ = 280 min and 360 min. In cell culture medium, only 3a-d degraded to 67-78 % after 72 h. However, the uptake studies showed that approximatly 80 % of the esters were accumulated in the cell within the first 1-3 h of incubation. Therefore, it can be concluded that the intact LEAD-esters and LEAD-amides caused the biological effects. The compounds were non-cytotoxic and efficiently sensitized KD225 (K562-resistant) CML cells to Imatinib at a half-maximal sensitizing concentration (SC50) of 1.5-2.9 μM (ester derivatives) and 1.3-11.2 μM (amide derivatives).
期刊介绍:
The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers.
A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.